Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome

Visceral Adiposity Index Levels in Polycystic Ovary Syndrome Subtypes

We aimed to investigate visceral adiposity index (VAI) in patients with different phenotype of policystic ovary syndrome (PCOS) and to compare healthy controls.

Study Overview

• Status: Completed
• Conditions: Polycystic Ovary Syndrome; Visceral Adiposity Index

Detailed Description

Polycystic ovary syndrome; Metabolic disorders such as insulin resistance, dyslipidemia, glucose intolerance, hypertension and obesity are often accompanied, and increased inflammation is the main characteristic of this syndrome. While the presence or absence of PCOS was important until recently, recent studies have shown that metabolic changes and inflammation occur at different degrees in different subtypes of PCOS. Therefore, PCOS cases are divided into 4 subtypes. These; Subtype 1 has hyperandrogenemia + oligoanovulation + PCO appearance on ultrasonography (USG), Subtype 2 has hyperandrogenemia + oligoanovulation, Subtype 3 has hyperandrogenemia + PCO appearance on USG, and Subtype 4 has oligoanovulation + PCO appearance on USG. As the subtype number of polycystic ovary syndrome decreases, the severity and frequency of metabolic disorders and inflammation accompanying polycystic ovary syndrome increase.

Patients with polycystic ovary syndrome often have abdominal obesity, which leads to hypertension, dyslipidemia, impaired glucose tolerance, Type 2 Diabetes and metabolic syndrome, which predisposes to the development of cardiovascular disease. Visceral adiposity is associated with abnormal lipid levels, proinflammatory activity, insulin resistance, and hyperandrogenism. Increased visceral adiposity increases the risk of metabolic syndrome, Type 2 Diabetes, and cardiovascular events in women with PCOS; It also aggravates ovulation dysfunction and hyperandrogenism.

Visceral adiposity index (VAI) is a simple marker of visceral adipose tissue dysfunction and visceral adiposity and is associated with insulin resistance, hyperinsulinemia, hyperandrogenism and anovulation. Visceral adiposity index (VAI) is one of the new methods used to determine visceral adiposity and predict cardiometabolic risks in patients. Visceral adiposity index is the strongest marker determining metabolic syndrome in both obese and non-obese PCOS patients. Visceral adiposity index is calculated with the formula [Waist circumference / (36.58 + (1.88xBMI)] x (Triglyceride/0.81) x (1.52/HDL-C). Visceral adiposity index is used in the clinical presentations of PCOS and treatment success. It is reported to be a useful marker that enables early detection and intervention of the risk of metabolic syndrome in women. Since there are different metabolic effects in different subtypes of PCOS, we aimed to investigate whether there is a difference between visceral adiposity indexes in different PCOS subtypes.

• Study Type: Observational
• Enrollment (Actual): 300

Contacts and Locations

Study Locations

• Turkey
  • Usak, Turkey, 64100
    • Uşak Training and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Woman aged between 18 and 35, age-matched between groups, diagnosed with PCOS and without a known cancer diagnosis, liver and kidney failure, not taking medications that would affect HDL, TG levels and insulin resistance and without active infection.

Description

Inclusion Criteria:

1. Patients who applied for reasons such as hair growth, acne, menstrual irregularity or infertility and were diagnosed with PCOS after examination, biochemical, hormonal and sonographic tests,
2. Female patients between the ages of 18-35,
3. Patients without known cancer, liver or kidney failure,
4. Patients who do not take medications that will affect HDL, TG levels and insulin resistance,
5. Female patients without active infection will be included. -

Exclusion Criteria:

1. Female patients under eighteen years of age and >35 years of age,
2. Patients with known cancer, liver and kidney failure,
3. Patients taking medications that will affect HDL, TG levels and insulin resistance,
4. Patients with active infection will not be included in the study. -

Study Plan

How is the study designed?

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort
PCOS Subtype 1; Hyperandrogenemia+oligoanovulation+PCO appearance on USG
PCOS Subtype 2; Hyperandrogenemia+oligoanovulation
Controls; Healthy controls between aged 18-35 years
PCOS Subtype 3; Hyperandrogenemia+PCO appearance on USG
PCOS Subtype 4; Oligoanovulation+PCO appearance on USG

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome	Since there are different metabolic effects in different subtypes of polycystic ovary syndrome; In this study we aimed to investigate whether there is a difference between VAI in different PCOS subtypes and the difference between these subtypes and the healthy group.	Eight months

Collaborators and Investigators

• Sponsor: Uşak University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): September 1, 2022
• Study Completion (Actual): July 20, 2023

Study Registration Dates

• First Submitted: April 4, 2024
• First Submitted That Met QC Criteria: April 4, 2024
• First Posted (Actual): April 10, 2024

Study Record Updates

• Last Update Posted (Actual): April 10, 2024
• Last Update Submitted That Met QC Criteria: April 4, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Polycystic ovary syndrome; Visceral Adiposity Index; PCOS Subtypes
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Endocrine System Diseases; Disease; Ovarian Cysts; Cysts; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Polycystic Ovary Syndrome; Syndrome; Obesity
• Other Study ID Numbers: Usakpcos2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No